Social and economic burden of myelofibrosis – literature review
Medical Review (Med. pregled), 2023, 59(4), 23-29.
V. Stoeva1, K. Tashkov2
1 Specialized Hospital for Active Treatment of Hematology Diseases, Sofia
2 Faculty of Pharmacy, Medical University of Sofia
Abstract. The aim of the current literature review is to systematize studies on the social economic burden of myelofibrosis (MF) in our country and in the international literature. A search of publications was conducted in the PubMed and Google Scholar scientific literature databases and Bulgarian databases. Search key words were myelofibrosis, social burden, economic burden, cost of therapy. Twelve publications were identified and discussed in this review. The review of the literature on the social and economic burden of myelofibrosis shows that in Bulgaria, as well as worldwide, studies devoted to this issue are limited. The new studies are focused on the cost of treatment with JAK inhibitors; there is no information about the cost of treating the disease itself, and what is the social burden for society and patients. In conclusion, MF is associated with a significant economic burden and loss of labor productivity for the healthcare system, patients and their families. Continued efforts to develop more effective treatments to reduce the economic burden associated with MF and help patients and physicians improve the management of the disease are needed.
Key words: myelofibrosis, social burden, economic burden, cost of therapy
Address for correspondence: Vera Stoeva, e-mаil: vera.stoeva@gmail.com